Neurocrine Biosciences is Now Oversold (NBIX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Friday, shares of Neurocrine Biosciences, Inc. ( NBIX) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $12.90 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 40.3. A bullish investor could look at NBIX's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of NBIX shares:

Find out what 9 other oversold stocks you need to know about »

Neurocrine Biosciences, Inc. 1 Year Performance Chart

Looking at the chart above, NBIX's low point in its 52 week range is $8.57 per share, with $20.29 as the 52 week high point — that compares with a last trade of $13.08.

According to the ETF Finder at ETF Channel, NBIX makes up 1.11% of the SPDR S&P Biotech ETF ( XBI) which is trading relatively unchanged on the day Friday.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries